{
    "abstract": "Introduction: Diarrhea is a leading cause of mortality worldwide and rotavirus accounts for many of these deaths. As of August 2018, 96 countries have introduced rotavirus vaccines into their immunization programs. Two rotavirus vaccines, Rotarix\u00ae and RotaTeq\u00ae, have been WHO-prequalified since 2009, with Rotarix\u00ae being the preferred product of most Gavi-supported countries. ROTAVAC\u00ae and ROTASIIL\u00ae have both been prequalified recently. Materials and methods: We reevaluated the costs and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi and compared Rotarix\u00ae, ROTAVAC\u00ae, and ROTASIIL\u00ae in each country. For consistency with previously published analyses in these countries, we used the same Excel-based cohort model and much of the same data as the original analyses. We varied the expected price (with and without Gavi subsidy), wastage, and incremental health system costs associated with each vaccine. We assumed the same efficacy and waning assumptions following administration of two or three doses for the respective product. Results: The discounted cost per DALY averted compared to no vaccination ranged from 0.3 to 1.3 times GNI per capita for each vaccine. With the Gavi subsidy, the average cost-effectiveness ratios were below 0.3 times GNI per capita in all three countries. Though critical empirical cost data are not yet available, Rotarix\u00ae is the least costly and most cost-effective product in the countries examined in this modelling study. However, small decreases in the incremental health system cost for other products could result in cost and cost-effectiveness outcomes that match or surpass those of Rotarix\u00ae. Conclusion: Countries may wish to consider new rotavirus vaccines entering the market. Countries should carefully examine multiple product attributes including price and the incremental health system costs associated with each vaccine. These costs will vary by country and may be a defining factor in determining the least costly and most cost-effective product for the population.",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Li",
                    "initial": "L.",
                    "last": "Liu"
                },
                {
                    "first": "Shefali",
                    "initial": "S.",
                    "last": "Oza"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Hogan"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Perin"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Rudan"
                },
                {
                    "first": "Joy E.",
                    "initial": "J.E.",
                    "last": "Lawn"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Cousens"
                },
                {
                    "first": "Colin",
                    "initial": "C.",
                    "last": "Mathers"
                },
                {
                    "first": "Robert E.",
                    "initial": "R.E.",
                    "last": "Black"
                }
            ],
            "doi": "10.1016/S0140-6736(14)61698-6",
            "firstpage": "430",
            "issn": "01406736",
            "lastpage": "440",
            "pmid": "25280870",
            "pub_year": 2015,
            "title": "Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: An updated systematic analysis",
            "volume": "385"
        },
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Clark"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Black"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Tate"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Roose"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Kotloff"
                },
                {
                    "first": "Diana",
                    "initial": "D.",
                    "last": "Lam"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Blackwelder"
                },
                {
                    "first": "Umesh",
                    "initial": "U.",
                    "last": "Parashar"
                },
                {
                    "first": "Claudio",
                    "initial": "C.",
                    "last": "Lanata"
                },
                {
                    "first": "Gagandeep",
                    "initial": "G.",
                    "last": "Kang"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "Troeger"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Platts-Mills"
                },
                {
                    "first": "Ali",
                    "initial": "A.",
                    "last": "Mokdad"
                },
                {
                    "first": "Colin",
                    "initial": "C.",
                    "last": "Sanderson"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Lamberti"
                },
                {
                    "first": "Myron",
                    "initial": "M.",
                    "last": "Levine"
                },
                {
                    "first": "Mathuram",
                    "initial": "M.",
                    "last": "Santosham"
                },
                {
                    "first": "Duncan",
                    "initial": "D.",
                    "last": "Steele"
                },
                {
                    "first": "Yati",
                    "initial": "Y.",
                    "last": "Soenarto"
                },
                {
                    "first": "Celse",
                    "initial": "C.",
                    "last": "Rugambwa"
                },
                {
                    "first": "Evans",
                    "initial": "E.",
                    "last": "Mpabalwani"
                },
                {
                    "first": "Jason",
                    "initial": "J.",
                    "last": "Mwenda"
                },
                {
                    "first": "Jill",
                    "initial": "J.",
                    "last": "Murray"
                },
                {
                    "first": "Adam",
                    "initial": "A.",
                    "last": "Cohen"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1371/journal.pone.0183392",
            "issn": "19326203",
            "pmid": "28892480",
            "pub_year": 2017,
            "title": "Estimating global, regional and national rotavirus deaths in children aged <5 years: Current approaches, new analyses and proposed improvements",
            "volume": "12"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Jacqueline E.",
                    "initial": "J.E.",
                    "last": "Tate"
                },
                {
                    "first": "Anthony H.",
                    "initial": "A.H.",
                    "last": "Burton"
                },
                {
                    "first": "Cynthia",
                    "initial": "C.",
                    "last": "Boschi-Pinto"
                },
                {
                    "first": "Umesh D.",
                    "initial": "U.D.",
                    "last": "Parashar"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Agocs"
                },
                {
                    "first": "Fatima",
                    "initial": "F.",
                    "last": "Serhan"
                },
                {
                    "first": "Lucia",
                    "initial": "L.",
                    "last": "De Oliveira"
                },
                {
                    "first": "Jason M.",
                    "initial": "J.M.",
                    "last": "Mwenda"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Mihigo"
                },
                {
                    "first": "Pushpa",
                    "initial": "P.",
                    "last": "Ranjan Wijesinghe"
                },
                {
                    "first": "Nihal",
                    "initial": "N.",
                    "last": "Abeysinghe"
                },
                {
                    "first": "Kimberley",
                    "initial": "K.",
                    "last": "Fox"
                },
                {
                    "first": "Fem",
                    "initial": "F.",
                    "last": "Paladin"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1093/cid/civ1013",
            "firstpage": "S96",
            "issn": "10584838",
            "lastpage": "S105",
            "pmid": "27059362",
            "pub_year": 2016,
            "title": "Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013",
            "volume": "62"
        },
        "b0025": {
            "authors": [],
            "firstpage": "49",
            "issn": "00498114",
            "lastpage": "64",
            "pmid": "23424730",
            "pub_year": 2013,
            "title": "Rotavirus vaccines. WHO position paper - January 2013.",
            "volume": "88"
        },
        "b0030": null,
        "b0035": null,
        "b0040": null,
        "b0045": null,
        "b0050": null,
        "b0055": null,
        "b0060": null,
        "b0065": {
            "authors": [
                {
                    "first": "Clint",
                    "initial": "C.",
                    "last": "Pecenka"
                },
                {
                    "first": "Umesh",
                    "initial": "U.",
                    "last": "Parashar"
                },
                {
                    "first": "Jacqueline E.",
                    "initial": "J.E.",
                    "last": "Tate"
                },
                {
                    "first": "Jahangir A.M.",
                    "initial": "J.A.M.",
                    "last": "Khan"
                },
                {
                    "first": "Devin",
                    "initial": "D.",
                    "last": "Groman"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Chacko"
                },
                {
                    "first": "Md",
                    "initial": "M.",
                    "last": "Shamsuzzaman"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Clark"
                },
                {
                    "first": "Deborah",
                    "initial": "D.",
                    "last": "Atherly"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.05.087",
            "firstpage": "3982",
            "issn": "0264410X",
            "lastpage": "3987",
            "pmid": "28623028",
            "pub_year": 2017,
            "title": "Impact and cost-effectiveness of rotavirus vaccination in Bangladesh",
            "volume": "35"
        },
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "Naor",
                    "initial": "N.",
                    "last": "Bar-Zeev"
                },
                {
                    "first": "Jacqueline E.",
                    "initial": "J.E.",
                    "last": "Tate"
                },
                {
                    "first": "Clint",
                    "initial": "C.",
                    "last": "Pecenka"
                },
                {
                    "first": "Jean",
                    "initial": "J.",
                    "last": "Chikafa"
                },
                {
                    "first": "Hazzie",
                    "initial": "H.",
                    "last": "Mvula"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Wachepa"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Mwansambo"
                },
                {
                    "first": "Themba",
                    "initial": "T.",
                    "last": "Mhango"
                },
                {
                    "first": "Geoffrey",
                    "initial": "G.",
                    "last": "Chirwa"
                },
                {
                    "first": "Amelia C.",
                    "initial": "A.C.",
                    "last": "Crampin"
                },
                {
                    "first": "Umesh D.",
                    "initial": "U.D.",
                    "last": "Parashar"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Costello"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Heyderman"
                },
                {
                    "first": "Neil",
                    "initial": "N.",
                    "last": "French"
                },
                {
                    "first": "Deborah",
                    "initial": "D.",
                    "last": "Atherly"
                },
                {
                    "first": "Nigel A.",
                    "initial": "N.A.",
                    "last": "Cunliffe"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Beard"
                },
                {
                    "first": "Miren",
                    "initial": "M.",
                    "last": "Iturriza-Gomara"
                },
                {
                    "first": "Khuzwayo",
                    "initial": "K.",
                    "last": "Jere"
                },
                {
                    "first": "Carina",
                    "initial": "C.",
                    "last": "King"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Lewycka"
                },
                {
                    "first": "Osamu",
                    "initial": "O.",
                    "last": "Nakagomi"
                },
                {
                    "first": "Tambosi",
                    "initial": "T.",
                    "last": "Phiri"
                },
                {
                    "first": "Jennifer R.",
                    "initial": "J.R.",
                    "last": "Verani"
                },
                {
                    "first": "Cynthia G.",
                    "initial": "C.G.",
                    "last": "Whitney"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1093/cid/civ1025",
            "firstpage": "S220",
            "issn": "10584838",
            "lastpage": "S228",
            "pmid": "27059360",
            "pub_year": 2016,
            "title": "Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data",
            "volume": "62"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Clark"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Jauregui"
                },
                {
                    "first": "Ulla",
                    "initial": "U.",
                    "last": "Griffiths"
                },
                {
                    "first": "Cara B.",
                    "initial": "C.B.",
                    "last": "Janusz"
                },
                {
                    "first": "Brenda",
                    "initial": "B.",
                    "last": "Bola\u00f1os-Sierra"
                },
                {
                    "first": "Rana",
                    "initial": "R.",
                    "last": "Hajjeh"
                },
                {
                    "first": "Jon K.",
                    "initial": "J.K.",
                    "last": "Andrus"
                },
                {
                    "first": "Colin",
                    "initial": "C.",
                    "last": "Sanderson"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.05.045",
            "firstpage": "C19",
            "issn": "0264410X",
            "lastpage": "C29",
            "pmid": "23777686",
            "pub_year": 2013,
            "title": "TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination",
            "volume": "31"
        },
        "b0085": null,
        "b0090": null,
        "b0095": null,
        "b0100": null,
        "b0105": null,
        "b0110": null,
        "b0115": {
            "authors": [
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "Woods"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Revill"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Sculpher"
                },
                {
                    "first": "Karl",
                    "initial": "K.",
                    "last": "Claxton"
                }
            ],
            "doi": "10.1016/j.jval.2016.02.017",
            "firstpage": "929",
            "issn": "10983015",
            "lastpage": "935",
            "pmid": "27987642",
            "pub_year": 2016,
            "title": "Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research",
            "volume": "19"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Elliot",
                    "initial": "E.",
                    "last": "Marseille"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Larson"
                },
                {
                    "first": "Dhruv S.",
                    "initial": "D.S.",
                    "last": "Kazi"
                },
                {
                    "first": "James G.",
                    "initial": "J.G.",
                    "last": "Kahn"
                },
                {
                    "first": "Sydney",
                    "initial": "S.",
                    "last": "Rosen"
                }
            ],
            "doi": "10.2471/BLT.14.138206",
            "firstpage": "118",
            "issn": "00429686",
            "lastpage": "124",
            "pmid": "25883405",
            "pub_year": 2015,
            "title": "Thresholds for the cost\u2013effectiveness of interventions: Alternative approaches",
            "volume": "93"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Glassman"
                },
                {
                    "first": "Oscar",
                    "initial": "O.",
                    "last": "Ca\u00f1\u00f3n"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Silverman"
                }
            ],
            "doi": "10.1016/j.jval.2016.04.014",
            "firstpage": "913",
            "issn": "10983015",
            "lastpage": "920",
            "pmid": "27987640",
            "pub_year": 2016,
            "title": "How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America",
            "volume": "19"
        },
        "b0130": null
    },
    "body_text": [
        {
            "endOffset": 24955,
            "parents": [],
            "secId": "s0025",
            "sentence": "Detailed impact results are available in Table 3.",
            "startOffset": 24906,
            "title": "Results"
        },
        {
            "endOffset": 29078,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Fig. 1 shows the cost per DALY averted and total cost of vaccination program for each country and each vaccine, with or without Gavi subsidy.",
            "startOffset": 28937,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 17491,
            "parents": [],
            "secId": "s0005",
            "sentence": "Using previously published national cost-effectiveness studies allows us to leverage model inputs that have already been gathered, reviewed, and accepted by participating national stakeholders.",
            "startOffset": 17298,
            "title": "Introduction"
        },
        {
            "endOffset": 35130,
            "parents": [],
            "secId": "s0050",
            "sentence": "The analysis conducted here supports the continued use of Rotarix\u00ae in Gavi-eligible countries.",
            "startOffset": 35036,
            "title": "Discussion"
        },
        {
            "endOffset": 19885,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Tables 1 and S1 in supplementary materials highlight the characteristics and data inputs that remain consistent between the initial studies and this analysis.",
            "startOffset": 19727,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 34313,
            "parents": [],
            "secId": "s0050",
            "sentence": "Finally, this analysis does not examine all Gavi countries, but a selection based on prior modelling studies representing the three main transition phases of Gavi support.",
            "startOffset": 34142,
            "title": "Discussion"
        },
        {
            "endOffset": 34141,
            "parents": [],
            "secId": "s0050",
            "sentence": "It will be critical to empirically examine the actual delivery costs associated with the new vaccines, especially given the effects of relatively small changes in incremental health system costs.",
            "startOffset": 33946,
            "title": "Discussion"
        },
        {
            "endOffset": 26905,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "Rotarix\u00ae vaccine costs were only slightly higher followed by higher vaccine costs for ROTASIIL\u00ae.",
            "startOffset": 26809,
            "title": "Initial self-financing"
        },
        {
            "endOffset": 28066,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "Incremental health system costs for the two-dose course were again two-thirds of the three-dose course.",
            "startOffset": 27963,
            "title": "Preparatory transition"
        },
        {
            "endOffset": 17106,
            "parents": [],
            "secId": "s0005",
            "sentence": "Our objective is to compare the economic impacts of three vaccines (Rotarix\u00ae, ROTAVAC\u00ae, and ROTASIIL\u00ae) as though they were all available at the time of the original analyses.",
            "startOffset": 16932,
            "title": "Introduction"
        },
        {
            "endOffset": 19589,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Some parameters (e.g. severity of disease or treatment seeking rates) may differ across countries.",
            "startOffset": 19491,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 20681,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 20680,
                    "startOffset": 20676
                }
            },
            "secId": "s0020",
            "sentence": "Rotarix\u00ae has a two-dose schedule, while ROTAVAC\u00ae and ROTASIIL\u00ae have three-dose schedules [11].",
            "startOffset": 20587,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 27878,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "Considering only the cost of the vaccine from the country perspective, ROTAVAC\u00ae was the least expensive followed closely by Rotarix\u00ae and then ROTASIIL\u00ae.",
            "startOffset": 27726,
            "title": "Preparatory transition"
        },
        {
            "endOffset": 35637,
            "parents": [],
            "secId": "s0050",
            "sentence": "It provides health economic evidence that may help inform vaccine choice alongside a number of other factors.",
            "startOffset": 35528,
            "title": "Discussion"
        },
        {
            "endOffset": 20969,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 20968,
                    "startOffset": 20961
                },
                "b0090": {
                    "endOffset": 20968,
                    "startOffset": 20961
                }
            },
            "secId": "s0020",
            "sentence": "ROTAVAC\u00ae is modelled as a five-dose presentation, resulting in smaller storage volume but a higher wastage rate of 25% [17,18].",
            "startOffset": 20842,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 20305,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Non-severe disease results in recovery, whereas severe disease may result in recovery or death.",
            "startOffset": 20210,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 27725,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "The total cost of the program without accounting for the Gavi subsidy followed the same order.",
            "startOffset": 27631,
            "title": "Preparatory transition"
        },
        {
            "endOffset": 26545,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "Note the ordering by vaccine is different from the country and Gavi perspectives.",
            "startOffset": 26464,
            "title": "Initial self-financing"
        },
        {
            "endOffset": 23214,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "We assume Bangladesh stays in this phase over the duration of the analysis.",
            "startOffset": 23139,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 32438,
            "parents": [],
            "secId": "s0050",
            "sentence": "While Rotarix\u00ae was uniformly less costly and more cost-effective across these countries (assuming equal effectiveness across products), this finding is sensitive to relatively modest changes in input values.",
            "startOffset": 32231,
            "title": "Discussion"
        },
        {
            "endOffset": 20587,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Data inputs altered to account for alternative vaccine products include the number of doses, coverage of the third dose (if applicable), vaccine wastage, efficacy, incremental health system cost, and vaccine price (Table 2).",
            "startOffset": 20363,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 19726,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We do not explore these cross country differences here but the rationale for those input parameters can be found in the original papers.",
            "startOffset": 19590,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 20768,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "We incorporate the third dose for ROTAVAC\u00ae and ROTASIIL\u00ae with coverage at DTP3 levels.",
            "startOffset": 20682,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 32641,
            "parents": [],
            "secId": "s0050",
            "sentence": "Table 5 demonstrates that relatively small decreases in the incremental health system cost per dose for one of the new vaccines has the potential to tilt the economic benefits in favor of a new vaccine.",
            "startOffset": 32439,
            "title": "Discussion"
        },
        {
            "endOffset": 29526,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "As Gavi support declines, the vaccine program will become more expensive and less cost effective.",
            "startOffset": 29429,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 15746,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 15745,
                    "startOffset": 15738
                },
                "b0060": {
                    "endOffset": 15745,
                    "startOffset": 15738
                }
            },
            "secId": "s0005",
            "sentence": "However, ROTAVAC\u00ae (Bharat Biotech International Limited) and ROTASIIL\u00ae (Serum Institute of India) were recently prequalified by WHO [11,12].",
            "startOffset": 15606,
            "title": "Introduction"
        },
        {
            "endOffset": 33945,
            "parents": [],
            "secId": "s0050",
            "sentence": "To address these concerns, we conducted threshold analyses and indicated the incremental health system cost thresholds necessary for the new vaccines to meet the cost and cost-effectiveness results of Rotarix\u00ae.",
            "startOffset": 33735,
            "title": "Discussion"
        },
        {
            "endOffset": 25310,
            "parents": [],
            "secId": "s0025",
            "sentence": "Cost and cost-effectiveness results for the three countries and the three vaccines are displayed in Table 4.",
            "startOffset": 25202,
            "title": "Results"
        },
        {
            "endOffset": 36300,
            "parents": [],
            "secId": "s0055",
            "sentence": "A similar analysis examining non-Gavi countries paying higher vaccine prices would likely highlight additional economic benefits of the new vaccines.",
            "startOffset": 36151,
            "title": "Conclusion"
        },
        {
            "endOffset": 31562,
            "parents": [],
            "secId": "s0050",
            "sentence": "We did not undertake a head-to-head cost-effectiveness comparison of the vaccines, which would require more detailed vaccine performance and cost of delivery data and would not be appropriate for this analysis.",
            "startOffset": 31352,
            "title": "Discussion"
        },
        {
            "endOffset": 28600,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "The total cost of the program, without accounting for the Gavi subsidy, followed the same order.",
            "startOffset": 28504,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 14482,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 14481,
                    "startOffset": 14476
                },
                "b0030": {
                    "endOffset": 14481,
                    "startOffset": 14476
                }
            },
            "secId": "s0005",
            "sentence": "The World Health Organization (WHO) recommended rotavirus vaccination in all countries\u2019 national immunization programs in 2009, and as of August 2018 96 countries have introduced rotavirus vaccine [5,6].",
            "startOffset": 14279,
            "title": "Introduction"
        },
        {
            "endOffset": 31955,
            "parents": [],
            "secId": "s0050",
            "sentence": "Rotarix\u00ae resulted in the lowest-cost vaccination program from both the country and country plus Gavi perspective (Fig. 1).",
            "startOffset": 31833,
            "title": "Discussion"
        },
        {
            "endOffset": 33458,
            "parents": [],
            "secId": "s0050",
            "sentence": "This analysis is therefore driven by cost difference: particularly, by the interplay of doses per course, per-dose price, co-financing, and wastage rates.",
            "startOffset": 33304,
            "title": "Discussion"
        },
        {
            "endOffset": 31014,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The declines in incremental health system costs varies by product and scenario but ranges from declines of 14% to more than 100% in some instances.",
            "startOffset": 30867,
            "title": "Threshold analysis"
        },
        {
            "endOffset": 31697,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 31696,
                    "startOffset": 31692
                }
            },
            "secId": "s0050",
            "sentence": "Rather, our results indicate that choosing any of the vaccine products would be highly cost-effective relative to no vaccination [25].",
            "startOffset": 31563,
            "title": "Discussion"
        },
        {
            "endOffset": 15095,
            "parents": [],
            "secId": "s0005",
            "sentence": "India has introduced rotavirus vaccination in at least six states and will continue to expand the program nationally with domestically manufactured products (ROTAVAC\u00ae and ROTASIIL\u00ae).",
            "startOffset": 14913,
            "title": "Introduction"
        },
        {
            "endOffset": 33066,
            "parents": [],
            "secId": "s0050",
            "sentence": "This analysis has several limitations.",
            "startOffset": 33028,
            "title": "Discussion"
        },
        {
            "endOffset": 17929,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 17928,
                    "startOffset": 17921
                },
                "b0070": {
                    "endOffset": 17928,
                    "startOffset": 17921
                },
                "b0075": {
                    "endOffset": 17928,
                    "startOffset": 17921
                }
            },
            "secId": "s0015",
            "sentence": "The authors recently undertook impact and cost-effectiveness analyses of rotavirus vaccination in Bangladesh, Ghana, and Malawi [13\u201315].",
            "startOffset": 17793,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 19490,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Rather, we maintain consistency with the previously published studies to allow comparisons between vaccine products in the individual countries.",
            "startOffset": 19346,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 25551,
            "parents": [],
            "secId": "s0025",
            "sentence": "However, in most cases the two-dose vaccine Rotarix\u00ae was the most cost-effective followed by ROTAVAC\u00ae and then ROTASIIL\u00ae.",
            "startOffset": 25430,
            "title": "Results"
        },
        {
            "endOffset": 18525,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 18524,
                    "startOffset": 18520
                }
            },
            "secId": "s0015",
            "sentence": "Model inputs include demographic projections, disease incidence and mortality rates, vaccine efficacy (allowing for possible waning), vaccine coverage, timeliness of uptake, vaccine program costs, health service utilization rates, and treatment and households costs [16].",
            "startOffset": 18254,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 29719,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Ghana already pays a larger share of its vaccine costs so variation in the central panel shows a smaller change in cost and cost effectiveness for any of the vaccines as Gavi support declines.",
            "startOffset": 29527,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 35936,
            "parents": [],
            "secId": "s0055",
            "sentence": "This analysis demonstrates that all of the examined rotavirus vaccines would be highly cost-effective relative to no vaccination.",
            "startOffset": 35807,
            "title": "Conclusion"
        },
        {
            "endOffset": 14278,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 14222,
                    "startOffset": 14219
                },
                "b0020": {
                    "endOffset": 14277,
                    "startOffset": 14274
                }
            },
            "secId": "s0005",
            "sentence": "Rotavirus accounts for 24\u201337% of these deaths [3], resulting in an estimated 200,000 deaths annually [4].",
            "startOffset": 14173,
            "title": "Introduction"
        },
        {
            "endOffset": 24905,
            "parents": [],
            "secId": "s0025",
            "sentence": "Health benefits provided by rotavirus vaccination remain unchanged from prior studies and are similar across vaccines in the same country as we assume comparable protection conferred by different products.",
            "startOffset": 24700,
            "title": "Results"
        },
        {
            "endOffset": 26808,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "ROTAVAC\u00ae, however, was the least costly vaccine when considering the country and Gavi vaccine cost together.",
            "startOffset": 26700,
            "title": "Initial self-financing"
        },
        {
            "endOffset": 22718,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Malawi is an Initial Self-Financing country supporting a minimum co-financing of $0.20 per dose of vaccine.",
            "startOffset": 22611,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 33028,
            "parents": [],
            "secId": "s0050",
            "sentence": "This may not be feasible in all cases, but this analysis suggests additional study would be valuable in some settings.",
            "startOffset": 32910,
            "title": "Discussion"
        },
        {
            "endOffset": 28748,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Considering the cost of the vaccine from the country perspective, ROTAVAC\u00ae was the least expensive followed closely by Rotarix\u00ae and then ROTASIIL\u00ae.",
            "startOffset": 28601,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 25201,
            "parents": [],
            "secId": "s0025",
            "sentence": "With the Gavi subsidy, the average cost-effectiveness ratios were below 0.3 times GNI per capita in all three countries.",
            "startOffset": 25081,
            "title": "Results"
        },
        {
            "endOffset": 31998,
            "parents": [],
            "secId": "s0050",
            "sentence": "There is no single driver of this finding.",
            "startOffset": 31956,
            "title": "Discussion"
        },
        {
            "endOffset": 28833,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "The same ordering held when considering the country and Gavi vaccine costs together.",
            "startOffset": 28749,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 23859,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The average co-financing per dose over the period of analysis for Ghana is $0.78, $1.55, and $1.57 for ROTAVAC\u00ae, ROTASIIL\u00ae, and Rotarix\u00ae, respectively.",
            "startOffset": 23708,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 32137,
            "parents": [],
            "secId": "s0050",
            "sentence": "However, it is clear that the two-dose schedule for Rotarix\u00ae plays an important role in determining both vaccine and health systems costs.",
            "startOffset": 31999,
            "title": "Discussion"
        },
        {
            "endOffset": 23022,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Malawi is assumed to remain in this phase for the period of analysis.",
            "startOffset": 22953,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 23345,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The average cost per dose for Bangladesh is therefore $0.14, $0.29, and $0.29 for ROTAVAC\u00ae, ROTASIIL\u00ae, and Rotarix\u00ae, respectively.",
            "startOffset": 23215,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 27075,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "Incremental health system costs borne by countries include everything but the vaccine costs and procurement charges (e.g., international shipping and handling, wastage).",
            "startOffset": 26906,
            "title": "Initial self-financing"
        },
        {
            "endOffset": 19258,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The current analysis follows the prior studies as closely as possible and uses the same assumptions and data wherever possible, only varying inputs to reflect core characteristics of the new products that differ from Rotarix\u00ae.",
            "startOffset": 19032,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 30252,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "While Rotarix\u00ae resulted in the least expensive vaccination program across the examined countries, we undertook a threshold analysis to understand the consistency of this finding by varying the incremental health system cost per dose of the alternative products.",
            "startOffset": 29991,
            "title": "Threshold analysis"
        },
        {
            "endOffset": 22610,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 22609,
                    "startOffset": 22603
                },
                "b0105": {
                    "endOffset": 22609,
                    "startOffset": 22603
                }
            },
            "secId": "s0020",
            "sentence": "The second scenario assumes that each country would support a co-financing share per dose based on Gavi\u2019s co-financing policy and each country\u2019s co-financing status [8,21].",
            "startOffset": 22438,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 25741,
            "parents": [],
            "secId": "s0025",
            "sentence": "As such, we examine these costs by country at different stages of Gavi support.",
            "startOffset": 25662,
            "title": "Results"
        },
        {
            "endOffset": 22952,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 22951,
                    "startOffset": 22947
                }
            },
            "secId": "s0020",
            "sentence": "Per Gavi\u2019s policy, a country in this group selecting a three-dose rotavirus vaccine pays only two-thirds of the per-dose price, so a three-dose rotavirus vaccine represents the same co-financing commitment as a two-dose vaccine [22].",
            "startOffset": 22719,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 25080,
            "parents": [],
            "secId": "s0025",
            "sentence": "The discounted cost per DALY averted compared to no vaccination ranged from 0.3 to 1.3 times GNI per capita for all vaccines.",
            "startOffset": 24955,
            "title": "Results"
        },
        {
            "endOffset": 31832,
            "parents": [],
            "secId": "s0050",
            "sentence": "This work examined how costs may vary across vaccine products, countries at different levels of Gavi support, payer, and cost category.",
            "startOffset": 31697,
            "title": "Discussion"
        },
        {
            "endOffset": 19032,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All examined Rotarix\u00ae as a country-preferred product.",
            "startOffset": 18979,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 29970,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "However, there is variation in the cost effectiveness of the vaccine program.",
            "startOffset": 29893,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 27962,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "The same ordering held when considering the country and Gavi vaccine cost together.",
            "startOffset": 27879,
            "title": "Preparatory transition"
        },
        {
            "endOffset": 20023,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Individuals may or may not get disease.",
            "startOffset": 19984,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 33615,
            "parents": [],
            "secId": "s0050",
            "sentence": "Critically, we do not have precise estimates of incremental health systems cost per dose for current products or yet know how this cost may vary by product.",
            "startOffset": 33459,
            "title": "Discussion"
        },
        {
            "endOffset": 23138,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Bangladesh is a Preparatory Transition country, meaning that its co-financing share would increase by 15% per year.",
            "startOffset": 23023,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 16931,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 16930,
                    "startOffset": 16923
                },
                "b0070": {
                    "endOffset": 16930,
                    "startOffset": 16923
                },
                "b0075": {
                    "endOffset": 16930,
                    "startOffset": 16923
                }
            },
            "secId": "s0005",
            "sentence": "In this analysis, we reevaluate cost-effectiveness studies previously conducted in Bangladesh, Ghana, and Malawi [13\u201315].",
            "startOffset": 16810,
            "title": "Introduction"
        },
        {
            "endOffset": 36150,
            "parents": [],
            "secId": "s0055",
            "sentence": "We found Rotarix\u00ae to be the least costly and most cost-effective product in the three countries analyzed, but the differences can be small and subject to change with minor adjustments to uncertain input variables.",
            "startOffset": 35937,
            "title": "Conclusion"
        },
        {
            "endOffset": 16355,
            "parents": [],
            "secId": "s0005",
            "sentence": "In addition to differences in efficacy and safety among products, decision-makers may consider the potential costs of introduction and implementation and how this will affect cost-effectiveness.",
            "startOffset": 16161,
            "title": "Introduction"
        },
        {
            "endOffset": 21158,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 21157,
                    "startOffset": 21153
                }
            },
            "secId": "s0020",
            "sentence": "Some sources suggest wastage as high as 50% for this presentation, but we utilized a lower wastage to reflect the 5-dose presentation and expectations that wastage may fall over time [11].",
            "startOffset": 20970,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 27453,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "In Bangladesh, the total cost of the vaccination program with a Gavi subsidy ranged from approximately $42 million using Rotarix\u00ae to nearly $62 million using ROTASIIL\u00ae, and from almost $136 million using Rotarix\u00ae to approximately $200 million using ROTASIIL\u00ae without a subsidy.",
            "startOffset": 27176,
            "title": "Preparatory transition"
        },
        {
            "endOffset": 28937,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Incremental health system costs for the two-dose course were again two-thirds of the three-dose course.",
            "startOffset": 28834,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 24500,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The incremental health system cost per dose includes all non-vaccine-related costs such as vaccine distribution, cold chain expansion, staff training, and labor for service delivery or program management.",
            "startOffset": 24296,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 15179,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 15178,
                    "startOffset": 15175
                }
            },
            "secId": "s0005",
            "sentence": "Together, these six countries account for more than 30% of the world\u2019s infants [9].",
            "startOffset": 15096,
            "title": "Introduction"
        },
        {
            "endOffset": 22437,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 22436,
                    "startOffset": 22429
                },
                "b0100": {
                    "endOffset": 22436,
                    "startOffset": 22429
                }
            },
            "secId": "s0020",
            "sentence": "For this scenario we used a Gavi price-per-dose of US$2.02, $2.00, and $1.00 for Rotarix\u00ae, ROTASIIL\u00ae and ROTAVAC\u00ae, respectively [11,20].",
            "startOffset": 22301,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 23707,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Ghana entered the Accelerated Transition phase in 2017; assuming Ghana remains in this phase, the co-financing share increases linearly until full price is reached in 20221.",
            "startOffset": 23346,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 18836,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "For example, the Bangladesh analysis was undertaken prior to vaccine introduction and used projections for vaccine effectiveness.",
            "startOffset": 18707,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 22181,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "When comparing alternative vaccine products, we consider two alternative price scenarios in each country (Fig. S1 in supplementary materials).",
            "startOffset": 22039,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 24071,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "In addition to examining a variety of scenarios, we also undertook a threshold analysis to examine the robustness of our results by varying the incremental health system cost per dose of the alternative products.",
            "startOffset": 23859,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 26463,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "The total cost of the program without accounting for the subsidy, thus representing the joint country and Gavi cost, was again lowest using Rotarix\u00ae then followed by ROTAVAC\u00ae and ROTASIIL\u00ae.",
            "startOffset": 26274,
            "title": "Initial self-financing"
        },
        {
            "endOffset": 26699,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "If we only consider the cost of the vaccine from the country perspective, Rotarix\u00ae and ROTASIIL\u00ae were equally costly and the cost of ROTAVAC\u00ae was higher.",
            "startOffset": 26546,
            "title": "Initial self-financing"
        },
        {
            "endOffset": 30628,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Any incremental health system cost value below the value in the table would result in a cost and cost-effectiveness advantage for the associated vaccine product.",
            "startOffset": 30467,
            "title": "Threshold analysis"
        },
        {
            "endOffset": 25870,
            "parents": [],
            "secId": "s0025",
            "sentence": "Note that overall costs are not comparable across countries due to differing population sizes, birth cohorts, and other factors.",
            "startOffset": 25742,
            "title": "Results"
        },
        {
            "endOffset": 31149,
            "parents": [],
            "secId": "s0050",
            "sentence": "Rotavirus vaccination substantially reduces rotavirus illness, hospitalization, and death in each of the examined countries.",
            "startOffset": 31025,
            "title": "Discussion"
        },
        {
            "endOffset": 34463,
            "parents": [],
            "secId": "s0050",
            "sentence": "We believe these results are informative, but because they only reflect a specified time period, broader analyses would likely lead to new learnings.",
            "startOffset": 34314,
            "title": "Discussion"
        },
        {
            "endOffset": 17238,
            "parents": [],
            "secId": "s0005",
            "sentence": "Although RotaTeq\u00ae was an available product at the time, the previous studies each examined Rotarix\u00ae as a country-preferred product.",
            "startOffset": 17107,
            "title": "Introduction"
        },
        {
            "endOffset": 21255,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "ROTASIIL\u00ae is modelled as a two-dose presentation and a larger volume than Rotarix\u00ae and ROTAVAC\u00ae.",
            "startOffset": 21159,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 32230,
            "parents": [],
            "secId": "s0050",
            "sentence": "Interestingly, lower wastage rates (e.g. 5%) for ROTAVAC\u00ae had little impact on our findings.",
            "startOffset": 32138,
            "title": "Discussion"
        },
        {
            "endOffset": 20209,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "If they get rotavirus disease, it can be severe or non-severe, and treatment may or may not be received and can occur at informal (Bangladesh only), outpatient, or inpatient facilities.",
            "startOffset": 20024,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 17740,
            "parents": [],
            "secId": "s0005",
            "sentence": "Our aim is not to advocate for any particular product, but to explore the sensitivity of costs and cost-effectiveness of available products to a range of transparent assumptions within and across three countries at different levels of Gavi support.",
            "startOffset": 17492,
            "title": "Introduction"
        },
        {
            "endOffset": 35527,
            "parents": [],
            "secId": "s0050",
            "sentence": "This analysis does not seek to present a case for choosing one vaccine product over another but rather demonstrates that all examined rotavirus vaccines would have substantial health impact and be highly cost-effective relative to no vaccination.",
            "startOffset": 35281,
            "title": "Discussion"
        },
        {
            "endOffset": 35281,
            "parents": [],
            "secId": "s0050",
            "sentence": "Because each of the examined vaccine products is projected to be highly cost-effective, countries should consider the relative merits of all products.",
            "startOffset": 35131,
            "title": "Discussion"
        },
        {
            "endOffset": 20841,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 20840,
                    "startOffset": 20836
                }
            },
            "secId": "s0020",
            "sentence": "Rotarix\u00ae is modelled as a single-dose presentation with 5% wastage [11].",
            "startOffset": 20769,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 22300,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The first scenario assumes the country pays the Gavi price, which would remain constant for all years in the analysis.",
            "startOffset": 22182,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 25661,
            "parents": [],
            "secId": "s0025",
            "sentence": "Co-financing, which varies by Gavi status, is critical to understanding the costs of the vaccination programs.",
            "startOffset": 25551,
            "title": "Results"
        },
        {
            "endOffset": 15351,
            "parents": [],
            "secId": "s0005",
            "sentence": "The introduction of rotavirus vaccination in these countries promises to substantially reduce rotavirus disease burden and deaths but may pressure current vaccine supplies.",
            "startOffset": 15179,
            "title": "Introduction"
        },
        {
            "endOffset": 27151,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "Two-dose regimens were therefore two-thirds the cost of three-dose regimen.",
            "startOffset": 27076,
            "title": "Initial self-financing"
        },
        {
            "endOffset": 33734,
            "parents": [],
            "secId": "s0050",
            "sentence": "Likewise, estimates of wastage are uncertain for newer products and rates may fall over time as delivery is optimized.",
            "startOffset": 33616,
            "title": "Discussion"
        },
        {
            "endOffset": 17297,
            "parents": [],
            "secId": "s0005",
            "sentence": "As a result, we did not include RotaTeq\u00ae in this analysis.",
            "startOffset": 17239,
            "title": "Introduction"
        },
        {
            "endOffset": 32909,
            "parents": [],
            "secId": "s0050",
            "sentence": "The small magnitude of changes necessary and the general uncertainty around estimates of incremental health system costs per dose suggest that the economic benefits of alternative vaccines should be considered carefully, ideally through a country-specific evaluation.",
            "startOffset": 32642,
            "title": "Discussion"
        },
        {
            "endOffset": 18978,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Conversely, the Malawi analysis was undertaken after vaccine introduction and local effectiveness data were available to inform the analysis.",
            "startOffset": 18837,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 34570,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 34569,
                    "startOffset": 34565
                }
            },
            "secId": "s0050",
            "sentence": "As countries move closer to graduation and beyond, they may potentially lose access to \u201ctail\u201d prices [26].",
            "startOffset": 34464,
            "title": "Discussion"
        },
        {
            "endOffset": 28503,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "The total cost of the program to the country, accounting for the Gavi subsidy, was lowest using Rotarix\u00ae followed by ROTAVAC\u00ae and then ROTASIIL\u00ae.",
            "startOffset": 28358,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 18253,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "TRIVAC models consecutive birth cohorts to generate impact and cost-effectiveness estimates of rotavirus and other vaccines.",
            "startOffset": 18129,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 21371,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 21370,
                    "startOffset": 21366
                }
            },
            "secId": "s0020",
            "sentence": "When examining ROTASIIL\u00ae, we maintain the 5% wastage rates utilized in our prior country analyses of Rotarix\u00ae [11].",
            "startOffset": 21256,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 29428,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "This reflects Bangladesh\u2019s large population and an intermediate level of co-financing support from Gavi.",
            "startOffset": 29324,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 35036,
            "parents": [],
            "secId": "s0050",
            "sentence": "As these cost-effectiveness and impact studies are typically done for 10- or 20-year periods, it will be important for countries to consider the longer-term implications of vaccine choices as well as anticipated changes in the cost structure of countries\u2019 immunization programs.",
            "startOffset": 34758,
            "title": "Discussion"
        },
        {
            "endOffset": 14172,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 14171,
                    "startOffset": 14166
                },
                "b0010": {
                    "endOffset": 14171,
                    "startOffset": 14166
                },
                "b0015": {
                    "endOffset": 14171,
                    "startOffset": 14166
                }
            },
            "secId": "s0005",
            "sentence": "Diarrhea is a leading cause of childhood mortality worldwide, causing 9% of all under-5 deaths [1\u20133].",
            "startOffset": 14071,
            "title": "Introduction"
        },
        {
            "endOffset": 19345,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We do not attempt to harmonize inputs to make the results comparable across countries.",
            "startOffset": 19259,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 35796,
            "parents": [],
            "secId": "s0050",
            "sentence": "Country-specific analyses would be key to account for parameters driving results such as differences in incremental health system costs linked to any product.",
            "startOffset": 35638,
            "title": "Discussion"
        },
        {
            "endOffset": 22039,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "As data collection is beyond the scope of this analysis, we conducted a threshold analysis to examine how changes in incremental health system costs influence the results.",
            "startOffset": 21868,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 15605,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 15604,
                    "startOffset": 15600
                }
            },
            "secId": "s0005",
            "sentence": "Two rotavirus vaccines have been WHO-prequalified for global use since 2009: Rotarix\u00ae (a registered trademark of GlaxoSmithKline Biologicals SA, used under license by GlaxoSmithKline Inc.) and RotaTeq\u00ae (a registered trademark of Merck & Co., Inc.) [10].",
            "startOffset": 15352,
            "title": "Introduction"
        },
        {
            "endOffset": 16010,
            "parents": [],
            "secId": "s0005",
            "sentence": "This enables more manufacturers to enter the international market, increasing choice, and lowering supply pressure.",
            "startOffset": 15895,
            "title": "Introduction"
        },
        {
            "endOffset": 19983,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "In each analysis, the model tracks the designated birth cohorts over the first five years of life.",
            "startOffset": 19885,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 16648,
            "parents": [],
            "secId": "s0005",
            "sentence": "Such costs include the vaccine costs (e.g., price of the vaccine, international handling, transportation costs, and wastage) and costs to the health system (e.g., subnational vaccine distribution, cold chain expansion, and staff training and labor for service delivery or program management).",
            "startOffset": 16356,
            "title": "Introduction"
        },
        {
            "endOffset": 29157,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Rotarix\u00ae is the least costly and most cost effective product in all scenarios.",
            "startOffset": 29079,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 16160,
            "parents": [],
            "secId": "s0005",
            "sentence": "Product selection is a complex, multifactorial decision, and each introducing country assesses the advantages and disadvantages of competing products.",
            "startOffset": 16010,
            "title": "Introduction"
        },
        {
            "endOffset": 29892,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Finally, Malawi benefits from more Gavi support and has a smaller population so the cost of the vaccination program does not reach the same levels as Gavi support declines.",
            "startOffset": 29720,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 29323,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "In the left panel showing Bangladesh, the location of the vaccines is driven more by the inclusion of a Gavi subsidy or not rather than differences between vaccines.",
            "startOffset": 29158,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 18128,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Each analysis used the TRIVAC model, a static cohort model developed at the London School of Hygiene and Tropical Medicine with support from the Pan American Health Organization\u2019s ProVac Initiative.",
            "startOffset": 17930,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 24699,
            "parents": [],
            "secId": "s0025",
            "sentence": "The principal results of this study are health impact, cost-effectiveness, and cost comparisons among three rotavirus vaccine products for three countries at different phases of Gavi support.",
            "startOffset": 24508,
            "title": "Results"
        },
        {
            "endOffset": 26127,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "In Malawi, the total cost of the vaccine program with a Gavi subsidy ranged from $10.2 million using Rotarix\u00ae to $14.5 million using ROTAVAC\u00ae, and from $42.1 million using Rotarix\u00ae to $62.6 million using ROTASIIL\u00ae without a subsidy.",
            "startOffset": 25895,
            "title": "Initial self-financing"
        },
        {
            "endOffset": 34757,
            "parents": [],
            "secId": "s0050",
            "sentence": "Given the higher prices that non-Gavi countries currently pay for rotavirus vaccines, an analysis using higher prices for Rotarix\u00ae is likely to be more favorable to new vaccine products.",
            "startOffset": 34571,
            "title": "Discussion"
        },
        {
            "endOffset": 18706,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Analyses were adapted to country context and undertaken at different time points relative to vaccine introduction, which had implications for the use of local data in the analysis.",
            "startOffset": 18526,
            "title": "Model inputs and assumptions"
        },
        {
            "endOffset": 33246,
            "parents": [],
            "secId": "s0050",
            "sentence": "We do not have sufficient information to differentiate vaccine effectiveness or waning across products, and we assume all vaccine products have equivalent effectiveness over time.",
            "startOffset": 33067,
            "title": "Discussion"
        },
        {
            "endOffset": 33303,
            "parents": [],
            "secId": "s0050",
            "sentence": "Future studies may help clarify performance differences.",
            "startOffset": 33247,
            "title": "Discussion"
        },
        {
            "endOffset": 21573,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 21572,
                    "startOffset": 21568
                }
            },
            "secId": "s0020",
            "sentence": "While vaccine efficacy may differ by product, we do not believe there is sufficient evidence to differentiate by product in these countries, so we assume values consistent with the prior analyses [19].",
            "startOffset": 21372,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 14674,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 14673,
                    "startOffset": 14668
                },
                "b0035": {
                    "endOffset": 14673,
                    "startOffset": 14668
                }
            },
            "secId": "s0005",
            "sentence": "Gavi, the Vaccine Alliance provides support for rotavirus vaccination to eligible low- and middle-income countries (LMICs), and more than 40 countries have introduced with Gavi support [6,7].",
            "startOffset": 14483,
            "title": "Introduction"
        },
        {
            "endOffset": 27630,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0035",
            "sentence": "The total cost of the program, accounting for the Gavi subsidy and thus representing the cost to the country, was lowest using Rotarix\u00ae followed by ROTAVAC\u00ae and then ROTASIIL\u00ae.",
            "startOffset": 27454,
            "title": "Preparatory transition"
        },
        {
            "endOffset": 31351,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 31350,
                    "startOffset": 31343
                },
                "b0120": {
                    "endOffset": 31350,
                    "startOffset": 31343
                }
            },
            "secId": "s0050",
            "sentence": "In addition, each of the vaccine products is projected to be highly cost-effective relative to no vaccination from the country perspective, even with conservative cost-effectiveness thresholds [23,24].",
            "startOffset": 31150,
            "title": "Discussion"
        },
        {
            "endOffset": 16810,
            "parents": [],
            "secId": "s0005",
            "sentence": "As many countries transition away from Gavi financial support and toward self-financing of vaccines, these economic considerations become increasingly important.",
            "startOffset": 16649,
            "title": "Introduction"
        },
        {
            "endOffset": 25429,
            "parents": [],
            "secId": "s0025",
            "sentence": "Within an individual country, all vaccines had generally similar cost-effectiveness ratios compared to no vaccination.",
            "startOffset": 25311,
            "title": "Results"
        },
        {
            "endOffset": 21867,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Incremental health system cost per dose depends on various factors such as vaccine presentation, vaccine volume, cold chain and transport requirements, delivery process, and training needs, but quantifying these components precisely is challenging without extensive in-country data collection.",
            "startOffset": 21574,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 26273,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "The total cost of the program to the country, accounting for the Gavi subsidy, was lowest using Rotarix\u00ae followed by ROTASIIL\u00ae and then ROTAVAC\u00ae.",
            "startOffset": 26128,
            "title": "Initial self-financing"
        },
        {
            "endOffset": 14767,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 14766,
                    "startOffset": 14763
                }
            },
            "secId": "s0005",
            "sentence": "Numerous other countries have recently been approved for Gavi rotavirus vaccine support [8].",
            "startOffset": 14675,
            "title": "Introduction"
        },
        {
            "endOffset": 14912,
            "parents": [],
            "secId": "s0005",
            "sentence": "Recent approvals in countries with large birth cohorts include Afghanistan, Bangladesh, Democratic Republic of the Congo, Nigeria, and Pakistan.",
            "startOffset": 14768,
            "title": "Introduction"
        },
        {
            "endOffset": 28357,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "In Ghana, the total cost of the vaccination program with a Gavi subsidy ranged from approximately $68 million using Rotarix\u00ae to $100.5 million using ROTASIIL\u00ae and from nearly $90 million using Rotarix\u00ae to approximately $130 million using ROTASIIL\u00ae without a subsidy.",
            "startOffset": 28091,
            "title": "Accelerated transition"
        },
        {
            "endOffset": 24295,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Specifically, we reduced the incremental health system cost per dose for more costly products until the total cost of delivery and cost-effectiveness ratio were equivalent to the values obtained for the lowest cost product.",
            "startOffset": 24072,
            "title": "Alternative data inputs to reflect new vaccine products"
        },
        {
            "endOffset": 30466,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Table 5 illustrates the per-dose incremental health system cost as well as the percentage and absolute reduction in incremental health system costs at which costs and cost-effectiveness are equivalent to Rotarix\u00ae.",
            "startOffset": 30253,
            "title": "Threshold analysis"
        },
        {
            "endOffset": 15894,
            "parents": [],
            "secId": "s0005",
            "sentence": "WHO-prequalification ensures a product meets quality, safety and efficacy requirements allowing its purchase by international procurement agencies.",
            "startOffset": 15747,
            "title": "Introduction"
        },
        {
            "endOffset": 30866,
            "parents": [
                {
                    "id": "s0025",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "For example in Bangladesh with a Gavi subsidy, the incremental health system cost per dose of ROTAVAC\u00ae would have to be $0.16 (or 30%) lower than those of Rotarix\u00ae for the costs and cost-effectiveness of ROTAVAC\u00ae to be equal to Rotarix\u00ae.",
            "startOffset": 30629,
            "title": "Threshold analysis"
        }
    ],
    "docId": "S0264410X18314531",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Clint",
                "initial": "C.",
                "last": "Pecenka"
            },
            {
                "email": null,
                "first": "Frederic",
                "initial": "F.",
                "last": "Debellut"
            },
            {
                "email": null,
                "first": "Naor",
                "initial": "N.",
                "last": "Bar-Zeev"
            },
            {
                "email": null,
                "first": "Palwasha",
                "initial": "P.",
                "last": "Anwari"
            },
            {
                "email": null,
                "first": "Justice",
                "initial": "J.",
                "last": "Nonvignon"
            },
            {
                "email": null,
                "first": "Md",
                "initial": "M.",
                "last": "Shamsuzzaman"
            },
            {
                "email": null,
                "first": "Andrew",
                "initial": "A.",
                "last": "Clark"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.10.068",
        "firstpage": "7472",
        "issn": "0264410X",
        "keywords": [
            "Cost-effectiveness",
            "Gavi countries",
            "New vaccine introduction",
            "Rotavirus vaccines"
        ],
        "lastpage": "7478",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines"
    }
}